2017 Report form the Banff Foundation For Allograft Pathology
|
|
|
- Dorcas Johnston
- 6 years ago
- Views:
Transcription
1 2017 Report form the Banff Foundation For Allograft Pathology
2 The Banff Process: today A self-organizing consensus system in transplantation participate moderated Banff meetings thesis-antithesis-synthesis continuous work in progress refinement The Banff community Pathologists Nephrologists Tx-Surgeons Lab-Medicine established by consensus in 1991 The Banff lesions g, i, t, v - score tentative thresholds The Banff classification Current consensus for diagnostics New members Biostaticians Molecular Biologists Omics -specialists Mengel M. et al. Am J Transplant Oct;7(10): a Feedback concerning weaknesses and strengths by results from independent research Off-springs Liver Pancreas Composite Tissue Heart and Lung
3 Clinical Relevance and Impact of the Banff Process Google Scholar Citations of Banff reports 2013 Comandatuba, Brazil 5 Banff Foundation Definition of C4d -negative ABMR, adoption of molecular diagnostics 2015 Vancouver, Canada 5 Banff Foundation / CST Molecular Diagnostics consensus process 2017 Barcelona, Spain 5 Banff Foundation / SCT New end-points for Next-Generation Clinical Trials, role of i-ifta
4 History and Background: Banff Foundation For Allograft Pathology August 2011, 11 th Banff meeting, Paris: Identified unmet need for a formal organizational structure for the Banff process Nov 2011: MOU of Key opinion Leaders from the informal Banff Process October 2012: Grant application to ROTRF Creation of Swiss Foundation Legal Entity for the Banff Allograft Pathology Classification and Consensus Process January : Application for establishing Swiss non for profit foundation approved by Swiss authorities March 2013: ROTRF funding approval supplying three-year grant funding for establishing the Banff Foundation For Allograft Pathology : www. BANFF Foundation (CHE ) - Luzernerstrasse Meggen Switzerland Banking Details: Valiant Bank, Meggen, Banff Foundation, SWIFT/BIC: VABECH22XXX - IBAN: CH
5 Purpose of Banff Foundation The purpose of the Foundation is to promote collaborative research and refinement of knowledge in the field of transplantation pathology and related diagnostics worldwide. The foundation has a not for profit purpose and does not have to generate a profit. The ultimate objective of the research being supported is to facilitate knowledge translation and constant evolution of allograft pathology and related diagnostics in order to enhance clinical care and improve outcomes in transplant recipients. The results of the research activities supported will be published in the annual Banff Foundation report, on the Foundation website or in scientific journals, and will be presented at international scientific meetings. In particular, support will be provided to research projects of the Banff Working Groups (BWG) designed to create and evaluate data-driven and evidence-based refinement of the Banff classifications.
6 Banff Working Groups (BWG) Banff Working Groups: Require BOT approval Must address an unmet need in the Banff classification Need to be productive and report progress at Banff meetings Are temporary: discontinued if not productive in addressing the unmet need in reasonable time frame
7 Organizational structure of the Banff Foundation Board of Trustees: K. Solez (Chair), L. Racusen, D. Glotz, A. Demetris, M. Mengel, M. Mihatsch, D. Seron, B. Nankivell, A. Loupy Legal and Accounting Support reports to Secretary/Treasurer: Michael Mengel support reports to funding reports to Claudia Christen and IETRA Organ Steering committee Chairs: Composite tissues: Linda Cendales Heart : Patrick Bruneval / Jean-Paul Duong Kidney: Mark Haas / Alex Loupy Liver: Jake Demetris / Chris Bellamy Lung: David Hwang / Elizabeth Pavlisko Pancreas: Cinthia Drachenberg collaboration Scientific program committee: Chairs: Mark Haas and Alex Loupy Kidney: Mark Haas, Alex Loupy, Carmen Lefaucher Composite tissues: Linda Cendales Heart : Patrick Bruneval, Jean-Paul Duong Liver: Jake Demetris, Christopher Bellamy Lung: David Hwang, Elizabeth Pavlisko, Antoine Roux Pancreas/Islets: Cinthia Drachenberg and John Papadimitriou collaboration progress reports to Banff Working Group (BWG): TCMR/borderline Clinical and Laboratory Assessment of Highly Sensitized Patients Working Group for Evaluation of Adjunctive Diagnostics in Renal Allograft Biopsy Interpretation EM scoring Recurring GN TMA in transplants collaboration Budged proposal and accountability for meeting costs Local Conference chair: 2017 Meeting: Daniel Seron collaboration
8 2017 Financial Report Revenue: ROTRF grant: 120k Industry grants: 45k Banff meetings: 180k Donations: 0k Expenses: Foundation operation: 85k Banff meeting: 50k Banff Working Groups: 10k Publications: 15k No membership fees No endowment Current balance: +184,744 CHF
9 MOU developed in July 2016 Joint Oversight committee Joint Program committee
10 Acknowledgements Kim Solez and Lorraine Racusen Philip Halloran, Bob Colvin, Denis Glotz The Banff Community Funders and Sponsors of the Banff Foundation: ROTRF Novartis Astellas
Key issues in clinical trials in solid organ transplantation. New endpoints for New Generation Clinical Trials: A Summary of Banff proposals
Key issues in clinical trials in solid organ transplantation New endpoints for New Generation Clinical Trials: A Summary of Banff proposals Julio Pascual Hospital del Mar Barcelona Kim Solez The implementation
Faculty / Presenter Disclosure
Lifelong Learning, Faculty of Medicine & Dentistry Faculty / Presenter Disclosure Faculty: Kim Solez, M.D. Relationships with commercial interests: None The accreditation process was challenging. We almost
South Carolina Donor Registry Q & A
South Carolina Donor Registry Q & A How do I become a registered organ and tissue donor? There are several ways to register your legal consent to be a donor: 1.) At any SCDMV office or on the SCDMV web
Controlled Document Number: Version Number: 2 Controlled Document Sponsor: Controlled Document Lead:
University Hospitals Birmingham Policy on Human Tissue in Research NHS Foundation Trust CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 2 Controlled Document
New test for transplant rejection on the horizon
December 6, 2004 New test for transplant rejection on the horizon Vancouver Researchers at St. Paul s Hospital and Vancouver General Hospital are developing a revolutionary new test to diagnose and facilitate
Blood and Biopsy mrna Expression Signatures Can Distinguish Major Causes of Graft Injury in Liver Transplant Recipients
Northwestern University Feinberg School of Medicine Blood and Biopsy mrna Expression Signatures Can Distinguish Major Causes of Graft Injury in Liver Transplant Recipients Josh Levitsky, Dan Salomon, Sunil
OMICS international. Contact us at:
OMICS international OMICS International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS International hosts over 700 leading-edge
UNOS/OPTN Strategic Plan & Policy Engagement. Betsy J. Walsh, JD, MPH UNOS/OPTN President
UNOS/OPTN 2015-2018 Strategic Plan & Policy Engagement Betsy J. Walsh, JD, MPH UNOS/OPTN President 1 Outline 2015 2018 OPTN Strategic Plan Process Strategic Goals Strategic Objectives Resource Allocation
Transplantation Society. Transplantation Building Bridges to Excellence. World Wide Transplantation. Outline 9/28/2016
Transplantation Society Transplantation Building Bridges to Excellence How can we use our collective wisdom/education to optimize transplantation outcomes? development of the science and clinical practice
SRTR Technical Advisory Committee (STAC) Report to UNOS/OPTN Board
SRTR Technical Advisory Committee (STAC) Report to UNOS/OPTN Board November 16, 2009 Kim M. Olthoff, MD Chair, STAC Committee Slide 1 SRTR and OPTN: Complementary Roles SRTR Mission Research / Policy Evaluation
Presidential Commission for the Study of Bioethical Issues 2 nd meeting September
Presidential Commission for the Study of Bioethical Issues 2 nd meeting September 13 14 2010 David B. Weiner, Ph.D. Professor Department of Pathology and Laboratory Medicine University of Pennsylvania
CONSTITUTION OF THE GLOBAL ALLIANCE FOR GENOMICS AND HEALTH. Adopted, 2014
CONSTITUTION OF THE GLOBAL ALLIANCE FOR GENOMICS AND HEALTH Adopted, 2014 This Constitution sets forth the mission, objectives, and structure of the Global Alliance for Genomics and Health (Global Alliance).
Banff Initiative for Quality Assurance in Transplantation (BIFQUIT): Reproducibility of C4d Immunohistochemistry in Kidney Allografts
American Journal of Transplantation 2013; 13: 1235 1245 1093 1245 Wiley Periodicals Inc. C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12193
CTLM Cell Therapy Liaison Meetings
CTLM Cell Therapy Liaison Meetings October 2 nd, 2016 Olive J. Sturtevant, MHP, MT(ASCP)SBB,SLS, CQA(ASQ), CTLM Lead Designate, ISCT North America Legal & Regulatory Affairs Committee Mission of CTLM To
10:30-10:55 OPTN/UNOS Update, Maryl Johnson, MD, OPTN/UNOS Vice President. 10:55-12:00 Begin Discussion Agenda and OPTN/UNOS Committee Reports
AGENDA OVERVIEW Region 11 Meeting Embassy Suites Charlotte 4800 Tyron Street, Charlotte, NC 28217 March 15, 2019 (Note: All times except the start time are approximate. Actual times will be determined
Creating Terms of Reference for Not-for-Profit Board Committees
NOT-FOR-PROFIT RESOURCE CENTRE Creating Terms of Reference for Not-for-Profit Board Committees The use of committees or task groups by non-profit boards is a common practice. Committees can be useful for
Brain Death and Organ Transplantation in Japan: The Enactment of Organ Transplantation Act of Eiji Maruyama Kobe University Kobe, Japan
Brain Death and Organ Transplantation in Japan: The Enactment of Organ Transplantation Act of 1997 Eiji Maruyama Kobe University Kobe, Japan History of Japanese Laws Concerning Transplantation 1997.06:
Current status Health-RI
Gerrit Meijer, co-chair 08-12-2017, Utrecht, The Netherlands Current status Health-RI 12-12-2017 2 The problem Research Prevention/cure/care Innovation 12-12-2017 3 The cause: not technological, but social,
Executive Director: Annual Evaluation
Please rate the Executive Director on the following attributes. Executive Director: Annual Evaluation 1 1.1 1.2 1.3 Vision, Mission, and Strategies The Executive Director maintains a clear vision for the
HLA Part I: for the Clinician
2017 CST-Astellas Canadian Transplant Fellows Symposium HLA Part I: for the Clinician James Lan, MD, FRCPC, D(ABHI) Dr. Lan completed his nephrology training at the University of British Columbia. He then
Unicyte AG, regenerative medicine unit of Fresenius Medical Care, appoints world-leading experts to Scientific Advisory Board
Press Release Media Contact Martin Kunze T +49 6172 609-2115 martin.kunze@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com July 25, 2017 www.freseniusmedicalcare.com
The Corporate Representative's Presentation
The Corporate Representative's Presentation IFCC General Conference, Madrid, 2016-03-19 Rolf Hinzmann, MD, PhD Corporate Representative at the IFCC Executive Board Contact: rolf.hinzmann@roche.com Agenda
Digital Quality Summit. Charles Jaffe, MD, PhD CEO Health Level 7
Digital Quality Summit Charles Jaffe, MD, PhD CEO Health Level 7 Many Thanks to our Sponsors This is Jack s story This is Jack Honor student Football hero University-bound Jack complained to his Family
Hansa Medical AB Interim Report Second Quarter 2017 Business Update Presentation. July 20, 2017
Hansa Medical AB Interim Report Second Quarter 2017 Business Update Presentation July 20, 2017 2 Forward-looking statements This presentation may contain certain forward-looking statements and forecasts
What is biomedical science?
What is biomedical science? Biomedical science is the science at the heart of healthcare Everyone will use the services of biomedical scientists more than once during their life Samples taken by doctors
NMI Natural and Medical Sciences Institute at the University of Tübingen
NMI Natural and Medical Sciences Institute at the University of Tübingen Markwiesenstrasse 55, 72770 Reutlingen, Germany GPS-Coordinate: 48 29 38.24 N 9 08 02.73 O AGENDA Get updated about latest developments
ProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011
ProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011 1 Forward Looking Statement / Copyright notice / Disclaimer Forward Looking Statement This presentation contains forward-looking
Molecular Diagnostics: Local vs. Central Lab
Molecular Diagnostics: Local vs. Central Lab Robert B. Colvin, M.D. Massachusetts General Hospital Harvard Medical School Boston MA Banff Consensus Conference Barcelona March 30, 2017 Innovative Research
Cardiac Safety Research Consortium Annual Meeting. Future Areas of Focus & Opportunities 18 October 2016
Cardiac Safety Research Consortium Annual Meeting Future Areas of Focus & Opportunities 18 October 2016 CSRC MISSION To advance scientific knowledge on cardiac safety for new and existing medical products
Bipartisan Policy Center, Top Medical Innovation Priorities
Bipartisan Policy Center, Top Medical Priorities FDA: Advancing Medical is a Bipartisan Policy Center initiative led by former Senator Bill Frist, MD, former Congressman Bart Gordon, and BPC Health Initiative
Instructor: Laboratory Location: Contact Information: Website: Course Information: Research Interests: Instructor: Laboratory Location:
Exciting Research Opportunities For Undergraduate Honors Students At The University of Toledo College of Medicine and Life Sciences!!! Please see the list of faculty and research interests below for exciting
Hospital Accountability Planning Submission (HAPS) Process
Hospital Accountability Planning Submission (HAPS) Process Fiscal 2016/17 Presented in Fall 2015 Agenda 1. Context 2. HSAA Organizational Structure 3. Guiding Principles 4. Differences between 2015-16
Disclosures. Laboratory Stakeholders. IVD vs. LDT. FDA Regulation of Laboratory Developed Tests 10/2/2015. FDA Regulation of LDTs
Disclosures FDA Regulation of Laboratory Developed Tests Beaumont Health System, 24 th Annual Symposium on Molecular Pathology September 16, 2015 Roger D. Klein, MD JD Director, Molecular Pathology Clinical
Abstract P : Single dose acute toxicity and long-term biodistribution of perfluoropentane loaded iron doped silica nanoshells
Poster Session Abstracts Abstract P5-01-08: Single dose acute toxicity and long-term biodistribution of perfluoropentane loaded iron doped silica nanoshells Sarah L Blair, Alexander Liberman, Robert Viveros,
Solutions for Organ Failure
Solutions for Organ Failure It Takes an Analytics Collaborative IO Informatics and PROOF Centre Bob Stanley, Bruce McManus Innovator Presentation Do data analytics matter? Meteorological Tools The Cave
Des cellules-souches dans le poumon : pourquoi faire?
Des cellules-souches dans le poumon : pourquoi faire? Karl-Heinz Krause Dept. of Pathology and Immunology, Medical Faculty Dept. of Genetic and Laboratory Medicine, University Hospitals Geneva, Switzerland
Supplementary Materials for
www.sciencetranslationalmedicine.org/cgi/content/full/6/242/242cm6/dc1 Supplementary Materials for Sandbox: Building and Sharing Resources This PDF file includes: Mark David Lim E-mail: mlim@fastercures.org
6th Form Open Day 15th July 2015
6th Form Open Day 15 th July 2015 DNA is like a computer program but far, far more advanced than any software ever created. Bill Gates Welcome to the Open Day event at the Institute of Genetic Medicine
WHO Standard Organ Transplant Nomenclature Version 1.0
Standard Organ Transplant Nomenclature Version 1.0 Collaboratively Developed by and ICCBBA through the SONG project (Standardization of Organ Nomenclature Globally) Standard Organ Transplant Nomenclature
Preparedness for the inevitable: overcoming obstacles to a timely and effective R&D response. The WHO Blueprint Team
Preparedness for the inevitable: overcoming obstacles to a timely and effective R&D response The WHO Blueprint Team Context of the Blueprint WHO Executive Board 1 (January 2015) WHO Summit on Ebola R&D
FDA s Proposed Regulatory Changes to Laboratory-Developed Tests (LDTs) By Roz Sweeney, Ph.D., Nerac Analyst
FDA s Proposed Regulatory Changes to Laboratory-Developed Tests (LDTs) By Roz Sweeney, Ph.D., Nerac Analyst Introduction The FDA recently issued updated draft guidance for proposed regulatory changes affecting
Chair of the TMF Reference Model Steering Committee Co-founder of the TMF Reference Model with Lisa Mulcahy Chief Strategy Officer, Phlexglobal
Karen Roy Chair of the TMF Reference Model Steering Committee Co-founder of the TMF Reference Model with Lisa Mulcahy Chief Strategy Officer, Phlexglobal Paul Fenton Co-chair of the TMF Reference Model
Clinical and Translational Science Award (CTSA) program director/principal investigator
Splemental digital content for Kost RG, Leinberger-Jabari A, Evering TH, et al. Helping basic scientists engage with community Splemental Digital Appendix 1 Organizational Chart for Community-Engaged Research
United Kingdom Tissue Engineered - Skin Substitutes Market Outlook to 2020
United Kingdom Tissue Engineered - Skin Substitutes Market Outlook to Reference Code: GDMECC0860DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
Delivering on the Promise of Precision Medicine
Delivering on the Promise of Precision Medicine Bay Area Council Economic Institute Spring 2016 The Promise of Precision Medicine The Bay Area is one of the world s biggest hubs for innovation in research
Genomics and Healthcare A global and local perspective
Genomics and Healthcare A global and local perspective Kathryn North Director, Murdoch Childrens Research Institute Director, Victorian Clinical Genetics Service David Danks Professor of Child Health Research,
Data Mining for Genomic- Phenomic Correlations
Data Mining for Genomic- Phenomic Correlations Joyce C. Niland, Ph.D. Associate Director & Chair, Information Sciences Rebecca Nelson, Ph.D. Lead, Data Mining Section City of Hope National Medical Center
Comparative Oncology Program
The Problem: Non-Integrated Cancer Drug Development A Solution: Integration of Informative Non-Clinical Models of Cancer With Clinical Drug Development Efforts Companion Animal Malignancies as Comparative
The SWOG Biospecimen Bank: investing in the future of translational research
The SWOG Biospecimen Bank: investing in the future of translational research Nilsa C. Ramirez, MD, FCAP Contact PI, SWOG Biospecimen Bank Nationwide Children s Hospital 2011 Four SWOG Biospecimen Resources
Differentiation = Making specialized cells. Self-renewal = copying. What is a stem cell?
Differentiation = Making specialized cells What is a stem cell? What the photo shows A lump of metal and lots of different kinds of screws that can be made from it. Things to think about What is a specialized
INUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR REGENERATIVE MEDICINE
INUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR > SOLUTIONS AND HOPE Millions of people worldwide suffer from deadly diseases, chronic conditions and congenital disorders
U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE
U.S. FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH UPDATE Jeff Shuren Director Center for Devices and Radiological Health CDRH STRATEGIC PRIORITIES UPDATE The Center for Devices and Radiological Health
Module: Key Enabling Technologies for Biomedical Engineering
Module: Key Enabling Technologies for Biomedical Engineering Mandatory Courses New Frontiers in Medical Technology Coordinator: Laura González Credits: 6 This course offers an up-to-date report on current
Risk Mitigation in Breast Predictive Factor Testing. Elizabeth H Hammond MD
Risk Mitigation in Breast Predictive Factor Testing Elizabeth H Hammond MD Risk Defintion Risk is the opportunity for error, and risk of an inaccurate test result for the patient. Goal is the right test
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020 Reference Code: GDMECC0884DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
APPENDIX: TECHNICAL and OPERATIONAL ISSUES of the NEPTUNE. The FDA has not approved the use of WSI for the making primary
APPENDIX: TECHNICAL and OPERATIONAL ISSUES of the NEPTUNE PATHOLOGY IMAGING PROTOCOL Compliance with FDA and CLIA regulations The FDA has not approved the use of WSI for the making primary diagnosis of
Proteomics Division NEWSLETTER
American Association for Clinical Chemistry Proteomics Division NEWSLETTER Vol 7, No 2 December 2012 Message from the Chair: Proteomics Division on an upward trajectory! Steven H. Wong, Ph.D., Chair, Proteomics
Investor Presentation: Phase II Data for LCP Tacro. March 3, 2008
Investor Presentation: Phase II Data for LCP Tacro March 3, 2008 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. The words believe, expect, anticipate, intend, will, may,
Edwards Lifesciences. The global leader in patient-focused innovations for structural heart disease and critical care monitoring.
Edwards Lifesciences The global leader in patient-focused innovations for structural heart disease and critical care monitoring. Our History Founded by Miles Lowell Edwards in 1958 Inventor and visionary,
Exploring Sources of Variability Related to the Clinical Translation of Regenerative Engineering Products A Workshop
Board on Health Sciences Policy Forum on Regenerative Medicine Exploring Sources of Variability Related to the Clinical Translation of Regenerative Engineering Products A Workshop October 18, 2018 National
ISRAEL FREE TRADE ACT (IFTA) TECHNICAL INFORMATION FOR PRE-ASSESSMENT SURVEY (TIPS)
ISRAEL FREE TRADE ACT (IFTA) TECHNICAL INFORMATION FOR PRE-ASSESSMENT SURVEY (TIPS) TABLE OF CONTENTS PART 1 BACKGROUND...2 PART 2 IFTA GUIDANCE...2 2.1 EXAMPLES OF RED FLAG...3 2.2 EXAMPLES OF BEST PRACTICES...4
3rd World Nephrology and Therapeutics Congress
3rd World Nephrology and Therapeutics Congress About Conference 3rd World Nephrologyand Therapeutics Congress is going to be held in Philadelphia, USA during June 24-25, 2019. This is designed to bring
Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia
Published: 07:00 04.10.2007 GMT+2 /HUGIN /Source: Santhera Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649 Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia Liestal and
Strategic Plan Update on Activities IASLC Board of Directors
Strategic Plan 2018-2020 Update on Activities IASLC Board of Directors IASLC Strategic Plan 2018-2020 Scope of this document This document: 1) Summarizes the strategic planning activities and results started
National Museum of Health and Medicine
National Museum of Health and Medicine Accession Number: 2014.0006 Date of Records: 1951-1955 Size: 2 boxes Finding Aid by: Eric W. Boyle (2014) Otis Historical Archives MacNeill Collection Background
FACT - CIBMTR Data Audit Collaboration
FACT - CIBMTR Data Audit Collaboration Phyllis I. Warkentin, MD FACT Chief Medical Officer February 2017 FACT-CIBMTR Data Audit Collaboration History of data audits The joint FACT-CIBMTR Task Force becomes
Applying Simulation Optimization to Improve the Efficiency of Organ Allocation
Applying Simulation Optimization to Improve the Efficiency of Organ Allocation Nan Kong, Patricio Rocha Department of Industrial and Management Systems Engineering University of South Florida Outline Motivation
Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes
Downloaded from http:// on January 5, 2018. Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes Jeff Reeve, 1,2 Georg A. Böhmig, 3 Farsad
General Comments. Misinformation in Immunohistochemistry. Common Misinformation s in Immunohistochemistry 4/13/2017
Common Misinformation s in Immunohistochemistry Tri State Meeting May 3, 2017 Steven Westra Reagent Product Specialist Leica Biosystems Misinformation in Immunohistochemistry Flood of New Markers Diagnostic
Next Generation Molecular Diagnostics in Scotland. Dr Mark Drummond Haematologist, Beatson Cancer Centre
Next Generation Molecular Diagnostics in Scotland Dr Mark Drummond Haematologist, Beatson Cancer Centre Outline Precision Medicine Regulatory and Funding background in Scotland (briefly) The Gap in the
Annex VIIIB Paragraphs to be included in the Informed Consent Form for the collection and use of biological samples in clinical trials
DEPARTAMENTO DE MEDICAMENTOS DE USO HUMANO Annex VIIIB Paragraphs to be included in the Informed Consent Form for the collection and use of biological samples in clinical trials Version 20 th December
Veterinarian s Guide to Maximizing Biopsy Results
Veterinarian s Guide to Maximizing Biopsy Results Veterinarian s Guide to Maximizing Biopsy Results F. Yvonne Schulman DVM, Diplomate ACVP This edition first published 2016 2016 John Wiley & Sons, Inc.
Biomarker Utility and Acceptance in Drug Development and Clinical Trials: an FDA Regulatory Perspective
Biomarker Utility and Acceptance in Drug Development and Clinical Trials: an FDA Regulatory Perspective Chris Leptak, MD/PhD OND Biomarker and Companion Diagnostic Lead CDER/Office of New Drugs, Immediate
For personal use only
Shareholder Presentation Perth, WA Annual General Meeting 17th November 2016 Global leader in applying proteomics to MedTech ASX: PIQ 1 Disclaimer & forward-looking statements This Presentation is provided
MACRA: An Overview and Implications for Your Organization. Patrick J. Hurd, Esq. March 30, 2017 VASHRM
MACRA: An Overview and Implications for Your Organization Patrick J. Hurd, Esq. March 30, 2017 VASHRM MACRA: How Did We Get Here? MACRA: How Did We Get Here? Medicare Access and CHIP Reauthorization Act
Unit 1 Wellness and Homeostasis
Unit 1 Wellness and Homeostasis Organs and Tissues Available for Transplant Lesson Plan Objectives Connections to Curriculum Personal Perspectives/ Reflection Decision Making Working in Science B11-1-03
Interim Analysis of Randomized Clinical Trials. David L DeMets, PhD
Interim Analysis of Randomized Clinical Trials David L DeMets, PhD Need for Data Monitoring Phase I Trials (dose) Monitoring usually at local level Phase II Trials (activity) Most monitoring at local level
Ex vivo Lung Perfusion is an Essential Tool for Donor Optimization Debate: Pro
Ex vivo Lung Perfusion is an Essential Tool for Donor Optimization Debate: Pro AST CEOT Meeting Phoenix, AZ, February 2018 Shaf Keshavjee MD MSc FRCSC FACS Surgeon-in-Chief, University Health Network James
The Fifty-Sixth Annual Great Lakes Genomics Conference
The Fifty-Sixth Annual Great Lakes Genomics Conference DATES: May 17-18, 2018 LOCATION: ACCOMMODATION: Doubletree by Hilton: 89 Chestnut Street, University of Toronto Conference rates are not available
Centre on the Low-Carbon Growth Economy.
PUBLIC POLICY RESEARCH CENTRE Centre on the Low-Carbon Growth Economy. Energy in all its forms plays a fundamental and central role in the growth of Canada s economy. Canadians are significant producers,
Using Human Tissue in Translational Research and Clinical Trials
Using Human Tissue in Translational Research and Clinical Trials Dr Bridget S Wilkins NCRI Clinical Lead for Pathology Engagement (Consultant Histopathologist, St Thomas Hospital, London) Cellular and
A GLOBAL ECOSYSTEM FOR PRECISION MEDICINE. Connecting Patients, World-Class Hospitals, Physicians, BioMedical Companies, Academia and Researchers
A GLOBAL ECOSYSTEM FOR PRECISION MEDICINE Connecting Patients, World-Class Hospitals, Physicians, BioMedical Companies, Academia and Researchers 1 QPATHOLOGY (QP) ECOSYSTEM FOR PRECISION MEDICINE Patient
Against Lymphoma, I Take Action With LYSA.
Against Lymphoma, I Take Action With LYSA www.lysa-.org LYSA We are pleased to present LYSA (The Lymphoma Study Association), an academic cooperative group, which gathers every francophone medical team
icapture delivers THE YEAR IN REVIEW 2003/04
The icapture Centre s Organ Pathophysiology and Imaging Core has benefitted from a state-of-the-art CT scanner and a powerful Magnetic Resonance Image (MRI) machine purchased with dollars from the Canada
Biomarker Tests for Molecularly Targeted Therapies Key to Unlocking Precision Medicine Report from the National Academy of Medicine
Biomarker Tests for Molecularly Targeted Therapies Key to Unlocking Precision Medicine Report from the National Academy of Medicine Robert Nussbaum MD Chief Medical Officer, Invitae Corporation Former
COLORADO MULTI-PAYER COLLABORATIVE
1 COLORADO MULTI-PAYER COLLABORATIVE Charter UPDATED JANUARY 2017 2 Background The Colorado Multi-Payer Collaborative (Collaborative) includes public and private health care payers working to strengthen
A GLOBAL ECOSYSTEM FOR PRECISION MEDICINE. Connecting Patients, World-Class Hospitals, Physicians, BioMedical Companies, Academia and Researchers
A GLOBAL ECOSYSTEM FOR PRECISION MEDICINE Connecting Patients, World-Class Hospitals, Physicians, BioMedical Companies, Academia and Researchers 1 QPATHOLOGY (QPath) ECOSYSTEM FOR PRECISION MEDICINE Patient
EFQM: Internal Assessor. Contents are subject to change. For the latest updates visit Page 1 of 8
EFQM: Internal Assessor Page 1 of 8 Why Attend This course has been designed to prepare individuals to perform assessments of their organizations based on the EFQM Excellence Model and RADAR assessment
WHO International Clinical Trials Registry Platform (ICTRP)
WHO International Clinical Trials Registry Platform (ICTRP) Dr. Patrick Unterlerchner Department of Research Policy & Cooperation Geneva, Switzerland Statement of New York Workgroup (Various Stakeholders,
2010: A Cytology Odyssey
2010: A Cytology Odyssey Moderators: David B. Kaminsky, M.D., FIAC Barbara A. Crothers, D.O. Panelists: Daniel Kurtycz, M.D. E. Blair Holladay, Ph.D., CT(ASCP)CM Lynnette C. Savaloja, B.S., SCT (ASCP)
Background Paper for the Organ Expert Committee
Background Paper for the Organ Expert Committee What principles should guide an improved approach to organ allocation? Contents 1. Introduction... 2 A. Background... 2 2. Scope... 3 3. Current State...
UNC DIVISION OF NEPHROPATHOLOGY
UNC Division of Nephropathology The University of North Carolina School of Medicine Department of Pathology & Laboratory Medicine 09 Brinkhous-Bullitt Building, CB#7 Chapel Hill, NC 799-7 http://www.uncnephropathology.org
STRATEGIC PLAN
2015 2020 STRATEGIC PLAN American Epilepsy Society Dedicated to eradicating epilepsy and its consequences American Epilepsy Society The term strategy has many meanings. As we started to write these introductory
Strategic vision of Pharma Market
Strategic vision of Pharma Market Evolution 2012-2016 ACIP Presentation, Paris January 30, 2013 Introduction This presentation draws strategic orientations for pharma companies considering the expected
2016 FSHD International Research Consortium Daniel Perez, CEO & CSO, FSH Society
Muscular Dystrophy Coordinating Committee Meeting November 29, 2016 Neuroscience Center, Conference Room C/D 6001 Executive Blvd., Bethesda, Maryland 20892 2016 FSHD International Research Consortium Daniel
Established by: Dr Bridget S Wilkins On behalf of the ECMC Cellular Molecular Pathology Network Group
Established by: Dr Bridget S Wilkins On behalf of the ECMC Cellular Molecular Pathology Network Group Chairperson: Dr Karin Oien Cellular and Molecular Pathology are Vitally Important for Cancer Patients
Clinical Research Challenges in Developing Countries Aldrey Oliveira June 2nd 2016 Rio de Janeiro - Brazil https://www.youtube.com/watch?v=aomnvuycpue Challenges to Perform Clinical Trials in Developing
Internal Controls In Higher Education
Internal Controls In Higher Education A Queen s University Experience June 2016 Caroline Davis, Vice-Principal (Finance and Administration) Queen s University Carol Devenny Partner - PricewaterhouseCoopers
The patient must address the treating physician directly if he/she has any questions or requires information regarding the test results.
Order Form 1. Ordering of the FoundationOne Service The FoundationOne Service comprises the genetic analysis of tumour tissue and the compilation of a comprehensive report on any mutations found in the
Economic and Social Council
United Nations E/CN.3/2008/20 Economic and Social Council Distr.: General 7 December 2007 Original: English Statistical Commission Thirty-ninth session 26-29 February 2008 Item 4 (f) of the provisional